SCHEMBL423315

SCHEMBL423315

COC(=O)NC1CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4972944 0.98 EPHX1 (0.52)
SCHEMBL868764 0.95 EPHX1 (0.59)
SCHEMBL19426060 0.93 EPHX1 (0.63)
SCHEMBL15700754 0.93 EPHX1 (0.63)
SCHEMBL17169490 0.93 EPHX1 (0.63)
SCHEMBL19426065 0.93 EPHX1 (0.63)
SCHEMBL8393998 0.93 EPHX1 (0.63)
SCHEMBL1067515 0.93 EPHX1 (0.63)
Hydrochloric Acid SCHEMBL3927000 0.91 EPHX1 (0.61)
Bicarbonate SCHEMBL7105895 0.91 EPHX1 (0.55)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118598873-B Preparation method of chiral aza-quinoline compound 艾斯拓康生物医药(天津)有限公司 2024-11-19 CN disclosed
CN-118598873-B Preparation method of chiral aza-quinoline compound 艾斯拓康生物医药(天津)有限公司 2024-11-19 CN disclosed
CN-118598873-A Preparation method of chiral aza-quinoline compound 艾斯拓康生物医药(天津)有限公司 2024-09-06 CN disclosed
CN-118598873-A Preparation method of chiral aza-quinoline compound 艾斯拓康生物医药(天津)有限公司 2024-09-06 CN disclosed
US-20230382925-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2023-11-30 US disclosed
CN-113292535-B Method for preparing apaluamide intermediate and apaluamide 南京方生和医药科技有限公司 2022-07-01 CN disclosed
EP-3950692-A1 NOVEL TRICYCLIC COMPOUNDS AbbVie Inc. (US) 2022-02-09 EP disclosed
CN-113292535-A Method for preparing apaluamide intermediate and apaluamide 南京方生和医药科技有限公司 2021-08-24 CN disclosed
CN-107266419-A Specific amino pyridazine class, thing in combination, and its application method 赛特凯恩蒂克公司 2017-10-20 CN disclosed
CN-106986832-A Vegfr3 inhibitor 癌症治疗合作研究中心有限公司 2017-07-28 CN disclosed
US-20110251379-A1 COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS SATORI PHARMACEUTICALS, INC. (US) 2011-10-13 US disclosed
US-20110237540-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY CERULEAN PHARMA INC. 2011-09-29 US disclosed
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES INCYTE CORPORATION 2011-09-15 US disclosed
US-20110152512-A1 CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY CERULEAN PHARMA INC. 2011-06-23 US disclosed
US-20090163557-A1 Cannabinergic Lipid Ligands NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2009-06-25 US disclosed
CN-1930124-A Process for cross coupling indoles BOEHRINGER INGELHEIM PHARMA (US) 2007-03-14 CN disclosed
CN-1791599-A Hepatitis c inhibitor compounds BOEHRINGER INGELHEIM INT (DE) 2006-06-21 CN disclosed
US-5864043-A CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST KARL THOMAE GMBH (DE) 1999-01-26 US disclosed
US-5541229-A ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS DR. KARL THOMAE GMBH (DE) 1996-07-30 US disclosed
US-4386033-A BOILING, CONDENSATION OF VAPORS, CIRCULATION; SEPARATION BAYER AKTIENGESELLSCHAFT (DE) 1983-05-31 US disclosed